MMMaeve Malone

Maeve Malone

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maeve Malone has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ESRC Research Data Policy in a Changing Landscape

    by Paul Allanson, Angela Daly, Awais Elahi, Alistair Geddes, Maeve Malone, Niamh Nic Daeid, Lucille Tetley-Brown

    The Economic and Social Research Council (ESRC) is the UK’s largest funder of economic, social, behavioural, and human data science. ESRC research data policy is ‘intended to support ESRC grant holders who collect, produce and re-use data by defining researchers’ roles and responsibilities, as well as the roles and responsibilities of the ESRC and its data service providers.’ This paper reports on an independent review of this policy, commissioned and funded by the ESRC, and carried out by the authors, to make recommendations for an updated policy in the light of changes to both the data and legal/policy landscape. Following an initial scoping review, the study comprised an online survey of stakeholder views that was followed up by a series of focus groups, and an analysis of a sample of data management plans (DMPs). In this brief report, we concentrate on those aspects of our review, both in process and in substance, which are of most relevance to the data curation and data management community, and outline the next steps in the policy review process.

  • Open Access

    Doing ESRC Data Better: A study for the Economic and Social Research Council (ESRC)

    by University of Dundee, Paul Allanson, Angela Daly, Awais Elahi, Alistair Geddes, Maeve Malone, Niamh Nic Daeid, Lucille Tetley-Brown

    Ensuring open data and open science in changing times remains a priority for publicly funded social science research in the UK. Understanding the changing landscape is key to achieving this and implementing it through appropriate policies and practices.


  • Open Access

    Disclosure control of machine learning models from trusted research environments (TRE): New challenges and opportunities

    by Esma Mansouri-Benssassi, Simon Rogers, Smarti Reel, Maeve Malone, Jim Smith, Felix Ritchie, Emily Jefferson


  • Open Access

    When innovation outpaces regulations: The legal challenges for direct‐to‐patient supply of investigational medicinal products

    by Maeve Malone, Pamela Ferguson, Amy Rogers, Isla S. Mackenzie, David A. Rorie, Thomas M. MacDonald

    Aims: We profile the lack of specific regulation for direct‐to‐patient postal supply (DTP) of clinical trial medications (investigational medicinal products, IMPs) calling for increased efficiency of patient‐centred multi‐country remote clinical trials.Methods: Questionnaires emailed to 28 European Economic Area (EEA) Medical Product Licensing Authorities (MPLAs) and Swissmedic MPLA were analysed in 2019/2020. The questionnaire asked whether DTP of IMPs was legal, followed by comparative legal analysis profiling relevant national civil and criminal liability provisions in 30 European jurisdictions (including The Netherlands), finally summarising accessible COVID‐19‐related guidance in searches of 30 official MPLA websites in January 2021.Results: Twenty MPLAs responded. Twelve consented to response publication in 2021. DTP was not widely authorised, though different phrases were used to explain this. Our legal review of national laws in 29 EEA jurisdictions and Switzerland did not identify any specific sanctions for DTP of IMPs; however, we identified potential national civil and criminal liability provisions. Switzerland provides legal clarity where DTP of IMPs is conditionally legal. MPLA webpage searches for COVID‐19 guidance noted conditional acceptance by 19 MPLAs.Conclusions: Specific national legislation authorising DTP of IMPs, defining IMP categories, and conditions permitting the postage and delivery by courier in an EEA‐wide clinical trial, would support innovative patient‐centred research for multi‐country remote clinical trials. Despite it appearing more acceptable to do this between EU Member States, provided each EU MPLA and ethics board authorises it, temporary Covid‐19 restrictions in national Good Clinical Practice (GCP) guidance discourages innovative research into the safety and effectiveness of clinical trial medications.